ENTtoday
  • Home
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

When It Comes to Drug Development, What Do Our Dollars Buy?

by Marlene Piturro, PhD, MBA • July 1, 2006

  • Tweet
  • Email
Print-Friendly Version

Two studies look at trends in the cost and length of time spent developing new pharmaceuticals

You Might Also Like

No related posts.

Explore This Issue
July 2006

Since 1994, US spending on prescription drugs grew three times faster than healthcare spending as a whole. That affects payers, plans, patients, and physicians. Pharmaceutical companies claim that the cost of developing a new molecular entity (NME), often exceeding $1 billion, justifies high prescription drug prices. Two recent articles scrutinize that claim, examining the true costs of pharmaceutical innovation.

Development Costs: Is There One Answer?

Quantifying the cost of developing a new drug is a crucial question in the drug development debate. A recent analysis by Christopher P. Adams and Van V. Brantner entitled “Estimating the Cost of New Drug Development: Is It Really $802 Million?” notes that there is great variation in actual development costs for new drugs (Health Affairs 2006; 25 (2):429–436).

According to the authors, drug development costs averaged $868 million per NME, with a range of $500 million to over $2 billion (in year 2000 dollars), depending on therapeutic classes and the developing company. The authors compared their results with an earlier study by Joseph A. DiMasi and colleagues (Jrnl of Health Economics 2003: 151–185) that put the average drug development cost at $802 million, attributing the discrepancy of their findings to different data sets. They also noted that clinical costs of research and development (R&D) were fairly consistent with DiMasi’s data; $487 million for the new study versus $467 million for DiMasi.

When looking at the largest US pharmaceutical firms, Adams and Brantner found that firms developing the most new drugs outspent smaller rivals by $124 million for an NME. There were also significant differences in drug R&D by firm. One company developed 92 drugs at an average cost of $2.1 billion, as opposed to 34 drugs at an average cost of $521 million at a similar size firm.

Drugs with annual projected sales of $1 billion or more took one year less to develop than drugs with lower profit potential.

Figure. Pharmaceutical companies claim that the cost of developing a new molecular entity, often exceeding $1 billion, justifies high prescription drug prices, but two recent articles scrutinize that claim.

click for large version
Figure. Pharmaceutical companies claim that the cost of developing a new molecular entity, often exceeding $1 billion, justifies high prescription drug prices, but two recent articles scrutinize that claim.

Physician’s Perspective

Michael Goldrich, MD, of University Otolaryngology Associates in New Brunswick, NJ, who is a general pediatric and adult otolaryngologist with a subspecialty in laryngology, said he doesn’t object to pharmaceutical companies’ R&D spending because companies are investing in the future of clinical care.

Pages: 1 2 3 4 | Single Page

Filed Under: Departments, Health Policy, Medical Education, Practice Management Tagged With: cost, finance, healthcare reform, medication, pharmaceuticals, policy, treatmentIssue: July 2006

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Second Victims: The Effects of a Medical Error on Physicians Can Be Devastating
    • Advanced Degrees Can Help Otolaryngologists Better Understand the Business of Medicine
    • How to: A Dynamic Endonasal Columellar Strut Placement
    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?
    • Vertigo in the Elderly: What Does It Mean?
    • What Happens to Medical Students Who Don’t Match?
    • Complications for When Physicians Change a Maiden Name
    • Qualitative Research Shows How Patients Feel About Quality-of-Life Issues
    • How to: A Dynamic Endonasal Columellar Strut Placement
    • Second Victims: The Effects of a Medical Error on Physicians Can Be Devastating
    • Advanced Degrees Can Help Otolaryngologists Better Understand the Business of Medicine
    • Laser Laryngeal Surgery Is Safe Under THRIVE

Polls

Have you ever been, or have you ever known someone who has been a second victim?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2023 The Triological Society. All Rights Reserved.
ISSN 1559-4939